Top

Current Cardiology Reports

Published in:

01-07-2017 | Pericardial Disease (AL Klein, Section Editor)

New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets

Authors: Bo Xu, Serge C. Harb, Paul C. Cremer

Published in: Current Cardiology Reports | Issue 7/2017

Abstract

Purpose of Review

This review article aims to provide a contemporary insight into the pathophysiological mechanisms of and therapeutic targets for pericarditis, drawing distinction between autoinflammatory and autoimmune pericarditis.

Recent Findings

Recent research has focused on the distinction between autoinflammatory and autoimmune pericarditis. In autoinflammatory pericarditis, viruses can activate the sensor molecule of the inflammasome, which results in downstream release of cytokines, such as interleukin-1, that recruit neutrophils and macrophages to the site of injury. Conversely, in autoimmune pericarditis, a type I interferon signature predominates, and pericardial manifestations coincide with the severity of the underlying systemic autoimmune disease. In addition, autoimmune pericarditis can also develop after cardiac injury syndromes. With either type of pericarditis, imaging can help stage the inflammatory state. Prominent pericardial delayed hyperenhancement on magnetic resonance imaging suggests ongoing inflammation whereas calcium on computed tomography suggests a completed inflammatory cascade. In patients with ongoing pericarditis, treatments that converge on the inflammasome, such as colchicine and anakinra, have proved effective in recurrent autoinflammatory pericarditis, though further clinical trials with anakinra are warranted.

Summary

An improved understanding of the pathophysiological mechanisms of pericarditis helps unravel effective therapeutic targets for this condition.

Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ, et al. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015;16:12–31. doi:10.1093/ehjci/jeu128.CrossRefPubMed

•• Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American society of echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the society for cardiovascular magnetic resonance and society of cardiovascular computed tomography. J Am Soc Echocardiogr. 2013;26:965–1012.e15. doi:10.1016/j.echo.2013.06.023. An important guideline document on the management of pericardial conditions, with a focus on multimodality cardiovascular imaging assessment CrossRefPubMed

•• Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36:2921–64. doi:10.1093/eurheartj/ehv318. An important guideline document on pericardial diseases published by the European Society of Cardiology CrossRefPubMed

Imazio M. Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Expert Rev Clin Immunol. 2014;10:1487–92. doi:10.1586/1744666X.2014.965150.CrossRefPubMed

Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42:102–11. doi:10.1007/s12016-011-8294-7.CrossRefPubMedPubMedCentral

Imazio M. Pericardial involvement in systemic inflammatory diseases. Heart. 2011;97:1882–92. doi:10.1136/heartjnl-2011-300054.CrossRefPubMed

•• Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated pericarditis understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68:2311–28. doi:10.1016/j.jacc.2016.07.785. An important contemporary review of pericarditis with a focus on multimodality imaging assessment and pathophysiology CrossRefPubMed

Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103–7.CrossRefPubMed

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.CrossRefPubMed

10.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.CrossRefPubMedPubMedCentral

11.

•• Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. JAMA. 2016;316:1906. doi:10.1001/jama.2016.15826. The first published randomized trial evidence examining the efficacy of anakinra in recurrent pericarditis in a small number patients CrossRefPubMed

12.

van Kempen TS, Wenink MH, Leijten EFA, Radstake TRDJ, Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol. 2015;11:483–92.CrossRefPubMed

13.

Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12:168–76. doi:10.1038/nrcardio.2014.206.Cardiorheumatology.CrossRefPubMed

14.

Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology. 2006;45:4–7. doi:10.1093/rheumatology/kel313.CrossRef

15.

Miner JJ, Kim AHJ. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin. 2014;40:51–60. doi:10.1016/j.rdc.2013.10.003.CrossRef

16.

Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int J Cardiol. 2013;168:648–52. doi:10.1016/j.ijcard.2012.09.052.CrossRefPubMed

17.

Cevik C, Wilborn T, Corona R, Schanzmeyer E, Nugent K. Post-cardiac injury syndrome following transvenous pacemaker insertion: a case report and review of the literature. Hear Lung Circ. 2009;18:379–83. doi:10.1016/j.hlc.2009.04.001.CrossRef

18.

Alraies MC, Al Jaroudi W, Shabrang C, Yarmohammadi H, Klein AL, Tamarappoo BK. Clinical features associated with adverse events in patients with post-pericardiotomy syndrome following cardiac surgery. Am J Cardiol. 2014;114:1426–30. doi:10.1016/j.amjcard.2014.07.078.CrossRefPubMedPubMedCentral

19.

Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916–28. doi:10.1161/CIRCULATIONAHA.108.844753.CrossRefPubMed

20.

Khan AH. The postcardiac injury syndromes. Clin Cardiol. 1992;15:67–72. doi:10.1002/clc.4960150203.CrossRefPubMed

21.

Hoffman M, Fried M, Jabareen F, Vardinon N, Turner D, Burke M, et al. Anti-heart antibodies in Postpericardiotomy syndrome: cause or epiphenomenon? Autoimmunity. 2002;35:241–5. doi:10.1080/08916930290028166.CrossRefPubMed

22.

Douglas PS, Garcia MJ, Haines DE, Lai WW, Ragosta M, Ward RP, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Soc Echocardiogr. 2011;24:229–67. doi:10.1016/j.echo.2010.12.008.CrossRefPubMed

23.

Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, Rajeswaran J, et al. Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy: a case series with histopathological correlation. JACC Cardiovasc Imaging. 2011;4:1180–91. doi:10.1016/j.jcmg.2011.08.011.CrossRefPubMed

24.

Alraies MC, AlJaroudi W, Yarmohammadi H, Yingchoncharoen T, Schuster A, Senapati A, et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol. 2015;115:542–7. doi:10.1016/j.amjcard.2014.11.041.CrossRefPubMed

25.

Cremer PC, Tariq MU, Karwa A, Alraies MC, Benatti R, Schuster A, et al. Quantitative assessment of pericardial delayed hyperenhancement predicts clinical improvement in patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ Cardiovasc Imaging. 2015;8:1–8. doi:10.1161/CIRCIMAGING.114.003125.CrossRef

26.

Bogaert J, Francone M. Pericardial disease: value of CT and MR imaging. Radiology. 2013;267:340–56. doi:10.1148/radiol.13121059.CrossRefPubMed

27.

Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol. 2004;43:271–5. doi:10.1016/j.jacc.2003.08.032.CrossRefPubMed

28.

Gentry J, Klein AL, Jellis C. Transient constrictive pericarditis: current diagnostic and therapeutic strategies. Curr Cardiol Rep. 2016;18 doi:10.1007/s11886-016-0720-2.PubMed

29.

Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522–8. doi:10.1056/NEJMoa1208536.CrossRefPubMed

30.

Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, et al. Colchicine as first-choice therapy for recurrent pericarditis. Arch Intern Med. 2005;165:1987–91.CrossRefPubMed

31.

Horneffer P, Miller R, Pearson T, Rykiel M, Reitz B, Gardner T. The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292–6.PubMed

32.

Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart. 2015;101:1159–68. doi:10.1136/heartjnl-2014-306362.CrossRefPubMed

33.

Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123:1092–7. doi:10.1161/CIRCULATIONAHA.110.986372.CrossRefPubMed

34.

Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for Recurrent Pericarditis (CORP) a randomized trial. Ann Intern Med. 2011;155:409–14. doi:10.1111/trf.13134.CrossRefPubMed

35.

Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012–6. doi:10.1161/CIRCULATIONAHA.105.542738.CrossRefPubMed

36.

Leung YY, Yao Hui LL, Kraus VB. Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50. doi:10.1016/j.semarthrit.2015.06.013.CrossRefPubMedPubMedCentral

37.

Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:96. doi:10.1186/s12872-015-0068-3.CrossRefPubMedPubMedCentral

38.

Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for Recurrent Pericarditis (CORP) a randomized trial. Ann Intern Med. 2011:409–14. doi:10.1378/chest.13-0162.

39.

Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–7. doi:10.1016/S0140-6736(13)62709-9.CrossRefPubMed

40.

Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23. doi:10.1056/NEJMra050541.CrossRefPubMed

41.

Imazio M, Adler Y. Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev. 2013;18:355–60. doi:10.1007/s10741-012-9328-9.CrossRefPubMed

42.

Artom G, Koren-Morag N, Spodick DH, Brucato A, Guindo J, Bayes-De-Luna A, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J. 2005;26:723–7. doi:10.1093/eurheartj/ehi197.CrossRefPubMed

43.

Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. Corticosteroids for recurrent pericarditis high versus low doses: a nonrandomized observation. Circulation. 2008;118:667–71. doi:10.1161/CIRCULATIONAHA.107.761064.CrossRefPubMed

44.

Imazio M, Brucato A, Trinchero R, Shabetai R, Spodick D, Adler Y. Corticosteroid therapy for pericarditis: a double-edged sword. Nat Clin Pr Cardiovasc Med. 2008;5:118–9.CrossRef

45.

Elion GB. The purine path to chemotherapy. Science. 1989;244:41–7.CrossRefPubMed

46.

Sandborn W. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423–33.PubMed

47.

Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147:477–8. doi:10.1016/j.ijcard.2011.01.027.CrossRefPubMed

48.

Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013; doi:10.1002/14651858.CD001797.pub3.PubMed

49.

Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014; doi:10.1002/14651858.CD002063.pub6.PubMedCentral

50.

Salib M, Clayden R, Clare R, Wang G, Warkentin TE, Crowther MA, et al. Difficulties in establishing the diagnosis of immune thrombocytopenia: an agreement study. Am J Hematol. 2016;91:E327–9. doi:10.1002/ajh.24404.CrossRefPubMed

51.

Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–3.

52.

Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–6.

53.

Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med. 2016;17:263–9.CrossRef

54.

Moretti M, Buiatti A, Merlo M, Massa L, Fabris E, Pinamonti B, et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol. 2013;112:1493–8. doi:10.1016/j.amjcard.2013.06.036.CrossRefPubMed

55.

Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106–13. doi:10.1056/NEJM199301143280207.CrossRefPubMed

56.

Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–52.CrossRefPubMedPubMedCentral

57.

Zeft A, Spalding S. Autoinflammatory syndromes: fever is not always a sign of infection. Cleve Clin J Med. 2012;79:569–81.CrossRefPubMed

58.

Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196–204. doi:10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2.CrossRefPubMed

59.

Simon A, Bodar E, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004;117:208–10.CrossRefPubMed

60.

So A, de Smedt T, Revaz S, Tschopp J. Research article a pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:1–6. doi:10.1186/ar2143.CrossRef

61.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. JCR J Clin Rheumatol. 2009;15:161–4.CrossRefPubMed

62.

Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116:1277–9. doi:10.1016/j.amjcard.2015.07.047.CrossRefPubMed

63.

Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014; doi:10.1136/annrheumdis-2014-205990.PubMed

64.

Khandaker MH, Schaff HV, Greason KL, Anavekar NS, Espinosa RE, Hayes SN, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc. 2017;87:1062–70. doi:10.1016/j.mayocp.2012.05.024.CrossRef

Title: New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets
Authors: Bo Xu
Serge C. Harb
Paul C. Cremer
Publication date: 01-07-2017
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 7/2017
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-017-0866-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2017

Cardiovascular Risk in Survivors of Cancer

The Contemporary Role of Stents and Angioplasty for the Treatment of Infrapopliteal Disease in Critical Limb Ischemia

Pericardial Effusion and Cardiac Tamponade in the New Millennium

Targeted Nuclear Imaging Probes for Cardiac Amyloidosis

Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page